Table 1.
Baseline Data of Patients
| Characteristic | Anlotinib+S1 | Anlotinib | Test Value | P value |
|---|---|---|---|---|
| Sex (male/female) | 36/4 | 24/6 | χ2=1.4 | 0.308 |
| Years | 63.1±9.0 | 61.7±10.0 | t=0.43 | 0.67 |
| Smokers [n (%)] | 32 (80.0%) | 21 (70.0%) | χ2=0.932 | 0.334 |
| Smoking index | 1205.6±540.0 | 1100.0±616.4 | t=0.42 | 0.679 |
| Stage [n (%)] | χ2=0.280 | 0.991 | ||
| IIIB | 8 (20.0%) | 6 (20.0%) | ||
| IIIC | 10 (25.0%) | 7 (23.3%) | ||
| IVA | 8 (20.0%) | 5 (16.7%) | ||
| IVB | 10 (25.0%) | 9 (30.0%) | ||
| IVC | 4 (10.0%) | 3 (1.0%) | ||
| Performance Status | 3.0±0.6 | 2.9±0.6 | t=0.445 | 0.507 |
| Tumor location [n (%)] | χ2=0.932 | 0.334 | ||
| Central | 32 (80.0%) | 21 (70.0%) | ||
| Peripheral | 8 (20.0%) | 9 (30.0%) | ||
| Treatment line number [n (%)] | χ2=0.026 | 0.872 | ||
| Thirdly － line | 30 (75.0%) | 23 (76.7%) | ||
| Later － line | 10 (25.0%) | 7 (23.3%) | ||
| History of radiation therapy [n (%)] | 4 (10.0%) | 4 (13.3%) | χ2=0.188 | 0.717 |
| Pulmonary complications [n (%)] | ||||
| COPD | 6 (15.0%) | 5 (16.7%) | χ2=0.036 | 1.000 |
| Pneumonia | 15 (37.5%) | 12 (40.0%) | χ2=0.045 | 0.832 |